Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Adverse change in the risk/benefit.

Conditions

Non Small Cell Lung Cancer
Medullary Thyroid Cancer
RET Gene Mutation
Metastatic Solid Tumor
Advanced Solid Tumor

Interventions

DRUG: TPX-0046

Sponsor

Turning Point Therapeutics, Inc.